Sangamo Therapeutics news
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences:
- Jefferies Healthcare Conference
Date: Thursday, June 9 at 9:00 a.m. Eastern Time - Guggenheim I&I Spotlight Series – Treg-based Therapies
Date: Tuesday, July 12 at
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor.
“We are very grateful to the patient and investigator who partici
- Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the five treated patients
- In the first two dose cohorts, all four patients exhibited above normal α-Gal A activity, ranging from 3-fold to 15-fold above mean normal; patients in the first dose cohort have maintained elevated activity for one year and are now in the long-term follow-up study
- In the third dose cohort, the fifth patien
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted eight Sangamo abstracts for presentation at the 25th ASGCT Annual Meeting being held May 16-19, 2022, in-person in Washington, D.C. and in a virtual format. Presentations will focus on the progressio
- The Companies are collaborating on an orderly transition through first half of 2022 while Sangamo explores options to advance the program, including seeking a new partner
- Phase 1/2 PRECIZN-1 study of investigational SAR445136 expected to be completed as planned; final patients in study expected to be dosed in third quarter of 2022
- Preliminary proof-of-concept data presented at ASH 2021 showed no treatment-related AEs and treated patie